AstraZeneca PLC Announces Increased Coverage of BRILINTA (Ticagrelor) Through Plan Preferred Formulary Status on Medco Health Solutions, Inc.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that BRILINTA® (ticagrelor) tablets received Plan Preferred Tier 2 formulary access on Medco Health Solutions’ National commercial formulary and Preferred Brand formulary status on its Medicare Part D drug list.